JP2019532926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532926A5 JP2019532926A5 JP2019514217A JP2019514217A JP2019532926A5 JP 2019532926 A5 JP2019532926 A5 JP 2019532926A5 JP 2019514217 A JP2019514217 A JP 2019514217A JP 2019514217 A JP2019514217 A JP 2019514217A JP 2019532926 A5 JP2019532926 A5 JP 2019532926A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pridopidine
- skills
- administered
- der
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 28
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims 8
- 229950003764 pridopidine Drugs 0.000 claims 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 5
- 208000006289 Rett Syndrome Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 101710178912 Cyclin-dependent kinase-like 5 Proteins 0.000 claims 2
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims 2
- 102100020871 Forkhead box protein G1 Human genes 0.000 claims 2
- 101710087964 Forkhead box protein G1 Proteins 0.000 claims 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims 2
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical group Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010021588 Inappropriate affect Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 230000004598 abnormal eye movement Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000036626 alertness Effects 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- 229940050390 benzoate Drugs 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 230000004397 blinking Effects 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- 230000009193 crawling Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- -1 embonate Chemical compound 0.000 claims 1
- 229950005627 embonate Drugs 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 231100000001 growth retardation Toxicity 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims 1
- 208000000122 hyperventilation Diseases 0.000 claims 1
- 230000000870 hyperventilation Effects 0.000 claims 1
- 230000005022 impaired gait Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- 208000004141 microcephaly Diseases 0.000 claims 1
- 230000004973 motor coordination Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- 230000000474 nursing effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940075554 sorbate Drugs 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 229940114926 stearate Drugs 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| US62/395,854 | 2016-09-16 | ||
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532926A JP2019532926A (ja) | 2019-11-14 |
| JP2019532926A5 true JP2019532926A5 (enExample) | 2019-12-26 |
| JP6977029B2 JP6977029B2 (ja) | 2021-12-08 |
Family
ID=61619744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514217A Active JP6977029B2 (ja) | 2016-09-16 | 2017-09-15 | レット症候群を治療するためのプリドピジンの使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP4005570B1 (enExample) |
| JP (1) | JP6977029B2 (enExample) |
| CN (1) | CN109982686A (enExample) |
| AU (1) | AU2017326013B2 (enExample) |
| BR (1) | BR112019005040A2 (enExample) |
| CA (1) | CA3036984C (enExample) |
| DK (2) | DK4005570T3 (enExample) |
| ES (2) | ES2909557T3 (enExample) |
| HU (1) | HUE058314T2 (enExample) |
| IL (1) | IL265342B2 (enExample) |
| MX (1) | MX388845B (enExample) |
| PL (2) | PL3512506T3 (enExample) |
| WO (1) | WO2018053280A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2022524927A (ja) | 2019-02-02 | 2022-05-11 | ステモニックス インコーポレイティド | 創薬のためのヒトスフェロイドの使用方法 |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CA2937243C (en) * | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| EP3854785A1 (en) * | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2017
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Trotti | Restless legs syndrome and sleep-related movement disorders | |
| JP5675650B2 (ja) | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 | |
| AU2017308865B2 (en) | Therapeutic agents for neurodegenerative diseases | |
| JP2019524897A5 (enExample) | ||
| Simantirakis et al. | Atrial overdrive pacing for the obstructive sleep apnea–hypopnea syndrome | |
| EP4135690B1 (en) | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating, preventing and/or managing a neurological and/or psychiatric disorder | |
| MX2008012781A (es) | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. | |
| JP7387264B2 (ja) | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 | |
| JP2022553371A (ja) | α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法 | |
| EP3687518A1 (en) | Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations | |
| Giroux | Parkinson disease: managing a complex, progressive disease at all stages | |
| EP3113778B1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| Carano et al. | Glycopyrrolate and theophylline for the treatment of severe pallid breath-holding spells | |
| CN110225754A (zh) | 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法 | |
| JP2007517049A (ja) | 再発性病状を治療するための組成物および方法 | |
| NZ613418A (en) | Methods of preventing or reducing oxidative stress | |
| EA016007B1 (ru) | Лечение болезни паркинсона, обструктивного синдрома апноэ во сне, слабоумия с тельцами льюи, сосудистой деменции с помощью не содержащих имидазол алкиламиновых лигандов гистаминовых н-рецепторов | |
| Satishchandra et al. | Intermittent clobazam prophylaxis in hot water epilepsy is safe and effective: a prospective study | |
| Ahlskog | Cheaper, simpler, and better: tips for treating seniors with Parkinson disease | |
| WO2018022848A1 (en) | A2-73 as a therapeutic for insomnia, anxiety, and agitation | |
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| JP2023550093A (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| TWI826851B (zh) | 植物乳酸桿菌植物亞種ｐｓ１２８於製備治療芳香族l-胺基酸脫羧基酶缺乏症的藥物的用途 | |
| CN113453761A (zh) | 皮特-霍普金斯综合征的治疗 |